Salarius Announces Proposed Public Offering of Common Stock
July 29, 2020 16:15 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Pharmaceuticals to Expand Clinical Program to Target Additional Sarcomas in Ewing Sarcoma Phase 1/2 Clinical Trial
July 29, 2020 16:05 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Pharmaceuticals Announces Move to New Corporate Offices at Texas Medical Center
July 28, 2020 08:00 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Pharmaceuticals Names Nadeem Mirza, M.D., M.P.H., as Senior Vice President Clinical Development
July 23, 2020 08:00 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 23, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...
Salarius Pharmaceuticals Invited to Present Seclidemstat Research at Meeting of the Pediatric Oncology Subcommittee of the Food and Drug Administration’s Oncologic Drugs Advisory Committee
June 02, 2020 09:00 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, June 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Pharmaceuticals to Present Trial in Progress Poster at ASCO20 Virtual Scientific Program
May 27, 2020 08:00 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...
Salarius Pharmaceuticals Reports First Quarter 2020 Financial Results
May 14, 2020 16:05 ET
|
Salarius Pharmaceuticals, Inc.
Seclidemstat Advances Dose Escalation in Phase 1/2 Ewing Sarcoma Clinical Trial; On Track to Report Early Data in 2020 Conference Call and Live Audio Webcast Scheduled for Today, May 14, 2020, at...
Salarius Pharmaceuticals Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program
May 14, 2020 08:00 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 14, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced...
Salarius Pharmaceuticals to Report First Quarter 2020 Financial Results
May 07, 2020 16:05 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, May 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...
Salarius Pharmaceuticals Announces Board of Director Nominations in Advance of 2020 Annual Meeting
April 29, 2020 07:30 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, April 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, today...